A Phase 2 interventional study of RPL554 Suspension and Placebo in COPD, sponsored by Verona Pharma plc. Completed at 4 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-10-10.
Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 2, and was the 5th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
By country, each count listing its studies:
ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 79 across the 15 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 4 most frequent:
This study is registered under Verona Pharma plc, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma plc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 14th largest by enrollment, is one of 2 that started in 2018, is one of 18 in phase 2, and was the 14th registered.
Merck & Co., Inc’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2002.
1 of the studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270525Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEffect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Among Merck & Co., Inc’s 26 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol (Respimat) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will receive each of the three treatment combinations in a randomized sequence using a crossover design
RPL554 is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) which are known to have a role in modulating the inflammatory airway response in respiratory diseases, including COPD. PDE3 inhibitors act as bronchodilators whilst PDE4 inhibitors have anti-inflammatory properties and there is also evidence to suggest that combined inhibition of PDE3 and PDE4 can have additive or synergistic anti-inflammatory and bronchodilator. The two doses of RPL554 (1.5 mg and 6 mg)have been selected based on the results from prior studies investigating single and multiple ascending doses in healthy subjects, single doses in asthmatics, single/multiple ascending doses in COPD patients, and 3 days of dosing in COPD patients. These doses were demonstrated to be both effective as a bronchodilator and well tolerated.
The purpose of the study is to investigate if RPL554 has an additive bronchodilator effect when administered in combination with a commonly used anticholinergic/β-agonist combination medication, tiotropium/olodaterol (Respimat), in this patient population measured by the peak forced expiratory volume in one second (FEV1), and forced vital capacity (FVC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Post-bronchodilator (two puffs of salbutamol/albuterol followed by two puffs of ipratropium) spirometry at Screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Drug: RPL554 Suspension · Drug: Tiotropium/olodaterol (Respimat)
6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Drug: RPL554 Suspension · Drug: Tiotropium/olodaterol (Respimat)
Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Drug: Placebo · Drug: Tiotropium/olodaterol (Respimat)
A PDE3/4 inhibitor
A placebo solution
Drug pages: Tiotropium · Olodaterol
An anticholinergic/β-agonist combination medication
Change From Baseline in Peak FEV1 on Day 3
Change from baseline FEV1 to peak FEV1 (measured as the greatest value in the 4 hours post-dose after the morning dose) on Day 3
Time frame: Change from pre-dose at 5, 15 and 30 minutes and 1, 1.5, 2 & 4 hours on Day 3
Change From Baseline to Trough FEV1 on Day 4
Change from baseline to morning trough FEV1 on Day 4
Time frame: Change from pre-dose on Day 1 to pre-dose on Day 4
Change From Baseline in AUC0-4h FEV1 on Day 3
Change from baseline FEV1 to AUC FEV1 over 4 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters. (Note: Endpoint is AUC/interval length (average) so the units are in liters.)
Time frame: Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the morning dose)
Change From Baseline in AUC0-12h FEV1 on Day 3
Change from baseline in AUC over 12 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)
Time frame: Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 3 (after the morning dose)
Change From Baseline in Peak FEV1 on Day 1
Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the morning dose on Day 1
Time frame: Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 1 (after the morning dose), with the maximum change reported
Change From Baseline in Peak FEV1 After Evening Dose on Day 3
Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the evening dose on Day 3
Time frame: Change from pre-dose to each of the ollowing timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the evening dose), with the maximum change reported
Change From Baseline in AUC0-12h FEV1 on Day 1
Change from baseline FEV1 to AUC FEV1 over 12 hours post-dose after the morning dose on Day 1. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)
Time frame: Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 1 (after the morning dose)
Determination of Onset of Action on Day 1
Time to \>10% increase in FEV1 from pre-first dose, censored at 2 hours
Time frame: Change from pre-dose to the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2 hours on Day 1 (after the morning dose)
Residual Volume on Day 1
Change in residual volume during treatment
Time frame: Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)
Residual Volume on Day 3
Change in residual volume during treatment
Time frame: Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)
Functional Residual Capacity on Day 1
Change in functional residual capacity during treatment
Time frame: Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)
Functional Residual Capacity on Day 3
Change in functional residual capacity during treatment
Time frame: Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)
Specific Airway Conductance on Day 1
Change in specific airway conductance during treatment
Time frame: Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)
Specific Airway Conductance on Day 3
Change in specific airway conductance during treatment
Time frame: Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)
| Milestone | Low Dose RPL554 Then High Dose RPL554 Then Placebo | Low Dose RPL554 Then Placebo Then High Dose RPL554 | High Dose RPL554 Then Low Dose RPL554 Then Placebo | High Dose RPL554 Then Placebo Then Low Dose RPL554 | Placebo Then Low Dose RPL554 Then High Dose RPL554 | Placebo Then High Dose RPL554 Then Low Dose RPL554 |
|---|---|---|---|---|---|---|
| Started | 14 | 14 | 13 | 12 | 13 | 13 |
| Completed | 13 | 14 | 12 | 12 | 13 | 11 |
| Not completed | 1 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Alpha 1 antitrypsin deficiency | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Low Dose RPL554 Then High Dose RPL554 Then Placebo | Low Dose RPL554 Then Placebo Then High Dose RPL554 | High Dose RPL554 Then Low Dose RPL554 Then Placebo | High Dose RPL554 Then Placebo Then Low Dose RPL554 | Placebo Then Low Dose RPL554 Then High Dose RPL554 | Placebo Then High Dose RPL554 Then Low Dose RPL554 |
|---|---|---|---|---|---|---|
| Started | 13 | 14 | 12 | 12 | 13 | 11 |
| Completed | 13 | 14 | 12 | 12 | 13 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Low Dose RPL554 Then High Dose RPL554 Then Placebo | Low Dose RPL554 Then Placebo Then High Dose RPL554 | High Dose RPL554 Then Low Dose RPL554 Then Placebo | High Dose RPL554 Then Placebo Then Low Dose RPL554 | Placebo Then Low Dose RPL554 Then High Dose RPL554 | Placebo Then High Dose RPL554 Then Low Dose RPL554 |
|---|---|---|---|---|---|---|
| Started | 13 | 14 | 12 | 12 | 13 | 11 |
| Completed | 13 | 14 | 11 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 1 | 0 |
| Milestone | Low Dose RPL554 Then High Dose RPL554 Then Placebo | Low Dose RPL554 Then Placebo Then High Dose RPL554 | High Dose RPL554 Then Low Dose RPL554 Then Placebo | High Dose RPL554 Then Placebo Then Low Dose RPL554 | Placebo Then Low Dose RPL554 Then High Dose RPL554 | Placebo Then High Dose RPL554 Then Low Dose RPL554 |
|---|---|---|---|---|---|---|
| Started | 13 | 14 | 11 | 12 | 12 | 11 |
| Completed | 13 | 14 | 11 | 12 | 11 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Pre-dose fev1 not 20% baseline | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Low Dose RPL554 Then High Dose RPL554 Then Placebo | Low Dose RPL554 Then Placebo Then High Dose RPL554 | High Dose RPL554 Then Low Dose RPL554 Then Placebo | High Dose RPL554 Then Placebo Then Low Dose RPL554 | Placebo Then Low Dose RPL554 Then High Dose RPL554 | Placebo Then High Dose RPL554 Then Low Dose RPL554 |
|---|---|---|---|---|---|---|
| Started | 13 | 14 | 11 | 12 | 11 | 11 |
| Completed | 13 | 14 | 11 | 12 | 10 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
Change from baseline FEV1 to peak FEV1 (measured as the greatest value in the 4 hours post-dose after the morning dose) on Day 3
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| Change From Baseline in Peak FEV1 on Day 3 | 0.565 ± 0.2783 | 0.506 ± 0.2506 | 0.519 ± 0.2809 |
Change from baseline to morning trough FEV1 on Day 4
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| Change From Baseline to Trough FEV1 on Day 4 | 0.186 ± 0.2496 | 0.178 ± 0.2123 | 0.150 ± 0.2218 |
Change from baseline FEV1 to AUC FEV1 over 4 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters. (Note: Endpoint is AUC/interval length (average) so the units are in liters.)
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| Change From Baseline in AUC0-4h FEV1 on Day 3 | 0.429 ± 0.2518 | 0.390 ± 0.2246 | 0.377 ± 0.2485 |
Change from baseline in AUC over 12 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| Change From Baseline in AUC0-12h FEV1 on Day 3 | 0.390 ± 0.2426 | 0.347 ± 0.2219 | 0.337 ± 0.2447 |
Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the morning dose on Day 1
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| Change From Baseline in Peak FEV1 on Day 1 | 0.490 ± 0.2219 | 0.467 ± 0.2393 | 0.445 ± 0.2306 |
Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the evening dose on Day 3
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| Change From Baseline in Peak FEV1 After Evening Dose on Day 3 | 0.453 ± 0.2625 | 0.405 ± 0.2581 | 0.324 ± 0.2211 |
Change from baseline FEV1 to AUC FEV1 over 12 hours post-dose after the morning dose on Day 1. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| Change From Baseline in AUC0-12h FEV1 on Day 1 | 0.333 ± 0.1815 | 0.308 ± 0.1854 | 0.303 ± 0.1920 |
Time to \>10% increase in FEV1 from pre-first dose, censored at 2 hours
| minutes | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| Determination of Onset of Action on Day 1 | 10.0 (1 to 86) | 6.0 (4 to 117) | 11.0 (7 to 120) |
Change in residual volume during treatment
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol on Day 1 | 6 mg RPL554 and Tiotropium/Olodaterol on Day 1 | Placebo and Tiotropium/Olodaterol on Day 1 |
|---|---|---|---|
| Residual Volume on Day 1 | -0.469 ± 0.5521 | -0.408 ± 0.4803 | -0.377 ± 0.4810 |
Change in residual volume during treatment
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol on Day 3 | 6 mg RPL554 and Tiotropium/Olodaterol on Day 3 | Placebo and Tiotropium/Olodaterol on Day 3 |
|---|---|---|---|
| Pre-dose Day 3 | -0.323 ± 0.4548 | -0.313 ± 0.8946 | -0.184 ± 0.6274 |
| 1.25 hours | -0.648 ± 0.5173 | -0.510 ± 0.6304 | -0.510 ± 0.6257 |
| 8.25 hours | -0.526 ± 0.5594 | -0.481 ± 0.4994 | -0.471 ± 0.6186 |
| 12.25 hours | -0.353 ± 0.4561 | -0.236 ± 0.7566 | -0.094 ± 0.7118 |
Change in functional residual capacity during treatment
| Liters | 1.5 mg RPL554 and Tiotropium/Olodaterol on Day 1 | 6 mg RPL554 and Tiotropium/Olodaterol on Day 1 | Placebo and Tiotropium/Olodaterol on Day 1 |
|---|---|---|---|
| Functional Residual Capacity on Day 1 | -0.344 ± 0.5097 | -0.294 ± 0.4524 | -0.277 ± 0.4279 |
Change in functional residual capacity during treatment
| Liters | 1.5 mg RPL554 and Tiotropium/Oldaterol on Day 3 | 6 mg RPL554 and Tiotropium/Oldaterol on Day 3 | Placebo and Tiotropium/Oldaterol on Day 3 |
|---|---|---|---|
| 1.25 hours | -0.490 ± 0.4654 | -0.408 ± 0.6102 | -0.382 ± 0.5610 |
| 8.25 hours | -0.420 ± 0.5003 | -0.405 ± 0.6111 | -0.355 ± 0.6004 |
| 12.25 hours | -0.255 ± 0.4003 | -0.155 ± 0.7788 | -0.075 ± 0.5881 |
| Pre-dose on Day 3 | -0.278 ± 0.4340 | -0.206 ± 0.5925 | -0.163 ± 0.5742 |
Change in specific airway conductance during treatment
| 1/kPa*sec | 1.5 mg RPL554 and Tiotropium/Olodaterol on Day 1 | 6 mg RPL554 and Tiotropium/Olodaterol on Day 1 | Placebo and Tiotropium/Olodaterol on Day 1 |
|---|---|---|---|
| Specific Airway Conductance on Day 1 | 0.064 ± 0.1148 | 0.042 ± 0.0483 | 0.043 ± 0.1072 |
Change in specific airway conductance during treatment
| 1/kPa*sec | 1.5 mg RPL554 and Tiotropium/Olodaterol on Day 3 | 6 mg RPL554 and Tiotropium/Olodaterol on Day 3 | Placebo and Tiotropium/Olodaterol on Day 3 |
|---|---|---|---|
| Pre-dose Day 3 | 0.021 ± 0.608 | 0.046 ± 0.1060 | 0.016 ± 0.0890 |
| 1.25 hours | 0.064 ± 0.0824 | 0.050 ± 0.0682 | 0.049 ± 0.1193 |
| 8.25 hours | 0.059 ± 0.1312 | 0.048 ± 0.0733 | 0.037 ± 0.1125 |
| 12.25 hours | 0.029 ± 0.0774 | 0.032 ± 0.0629 | 0.021 ± 0.1071 |
Collected over From informed consent until the end of the study, approximately 2 months for each patient. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 mg RPL554 and Tiotropium/Olodaterol | 0/75 (0%) | 0/75 (0%) | 15/75 (20%) |
| 6 mg RPL554 and Tiotropium/Olodaterol | 0/74 (0%) | 1/74 (1.4%) | 15/74 (20.3%) |
| Placebo and Tiotropium/Olodaterol | 0/76 (0%) | 0/76 (0%) | 8/76 (10.5%) |
| Event | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/75 | 1/74 | 0/76 |
| Event | 1.5 mg RPL554 and Tiotropium/Olodaterol | 6 mg RPL554 and Tiotropium/Olodaterol | Placebo and Tiotropium/Olodaterol |
|---|---|---|---|
| HeadacheNervous system disorders | 5/75 | 5/74 | 1/76 |
| Ventricular extrasystolesCardiac disorders | 2/75 | 3/74 | 0/76 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/75 | 2/74 | 1/76 |
| HypertensionVascular disorders | 0/75 | 2/74 | 1/76 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/75 | 1/74 | 1/76 |
| ConstipationGastrointestinal disorders | 0/75 | 1/74 | 0/76 |
| Blood glucose increasedInvestigations | 0/75 | 1/74 | 0/76 |
| Electrocardiogram QT prolongedInvestigations | 1/75 | 1/74 | 0/76 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/75 | 1/74 | 0/76 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/75 | 1/74 | 1/76 |
| Age, Continuous(years) | Low Dose RPL554 Then High Dose RPL554 Then Placebo | Low Dose RPL554 Then Placebo Then High Dose RPL554 | High Dose RPL554 Then Low Dose RPL554 Then Placebo | High Dose RPL554 Then Placebo Then Low Dose RPL554 | Placebo Then Low Dose RPL554 Then High Dose RPL554 | Placebo Then High Dose RPL554 Then Low Dose RPL554 | Total |
|---|---|---|---|---|---|---|---|
| Median | 65.5 (43 to 75) | 64.5 (53 to 74) | 63.0 (45 to 74) | 63.0 (43 to 77) | 67.0 (49 to 76) | 61.0 (48 to 73) | 64.0 (43 to 77) |
| Sex: Female, Male(Participants) | Low Dose RPL554 Then High Dose RPL554 Then Placebo | Low Dose RPL554 Then Placebo Then High Dose RPL554 | High Dose RPL554 Then Low Dose RPL554 Then Placebo | High Dose RPL554 Then Placebo Then Low Dose RPL554 | Placebo Then Low Dose RPL554 Then High Dose RPL554 | Placebo Then High Dose RPL554 Then Low Dose RPL554 | Total |
|---|---|---|---|---|---|---|---|
| Female | 9 | 9 | 8 | 7 | 8 | 8 | 49 |
| Male | 5 | 5 | 5 | 5 | 5 | 5 | 30 |
| Race (NIH/OMB)(Participants) | Low Dose RPL554 Then High Dose RPL554 Then Placebo | Low Dose RPL554 Then Placebo Then High Dose RPL554 | High Dose RPL554 Then Low Dose RPL554 Then Placebo | High Dose RPL554 Then Placebo Then Low Dose RPL554 | Placebo Then Low Dose RPL554 Then High Dose RPL554 | Placebo Then High Dose RPL554 Then Low Dose RPL554 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 1 | 1 | 1 | 2 | 0 | 1 | 6 |
| White | 13 | 13 | 12 | 10 | 13 | 11 | 72 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Nov 2018, 3 months.
Results were first posted in Oct 2019, 10 months after primary completion.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 3 months is below that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensifentrine
Pulmonary Disease, Chronic Obstructive →